LOX inhibition disrupts a collagen-integrin-MYC axis as a translatable targeting strategy in invasive lobular carcinoma
Flaherty, R. L.; Hughes, F.; Sflomos, G.; Ronchi, C.; Kemp, H.; Roumeliotis, T.; Nicholas, A. A.; Ambrosini, G.; Ziehme, A.; Becker, S.; Zhang, Y.; Quinn, H. M.; Battista, L.; Padda, H.; Pezot, S.; Jouny, S.; Liu, Y.; Brough, R.; Marlow, R.; Iravani, M.; Okines, A.; Turner, N. C.; Stavrodimou, A.; Zaman, K.; Fiche, M.; Howard, B. A.; Choudhary, J. S.; Sanz-Moreno, V.; Isacke, C. M.; Perryman, L.; Jarolimek, W.; Haider, S.; Lord, C. J.; Brisken, C.
Show abstract
Invasive lobular carcinoma (ILC) accounts for 15% of breast cancers yet lacks specific therapy because ILCs are underrepresented in clinical trials and preclinical models are lacking. We established intraductal xenograft models to test whether the clinical pan-lysyl-oxidase PXS-5505, now in phase trials for myelofibrosis can exploit the collagen-rich matrix dependency created by CDH1 loss. PXS-5505 remodels fibrillar collagen, and halts tumor expansion and metastatic seeding across ER+ and triple negative models without systemic toxicity. Genome-wide CRISPR screens reveal ITGAV and ITGB5 as synthetic lethal partners of CDH1 and LOX inhibition downregulates their expression together with MYC, NF-{kappa}B, and AP-1 transcriptional programmes. Collagen fibre density/alignment, and MYC/AP-1 gene signatures serve as pharmacodynamic readouts of drug activity. These data uncover a tractable ECM-integrin-MYC axis in ILC and nominate PXS-5505, alone or with endocrine therapy, for window of opportunity trials in this understudied breast cancer subtype. One Sentence SummaryTargeting matrix remodelling in ILC inhibits ILC progression and alters multiple molecular endpoints, providing a translatable therapeutic strategy for this understudied subtype that requires better treatments.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 97%
- Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis 96%
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 96%
Similar papers in this journal
Similar papers in this journal
- Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer 97%
- Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment 96%
- A Multiomic Analysis Reveals How Breast Cancers Disseminated to the Bone Marrow Acquire Aggressive Phenotypes through Tumor-Stroma Tunnels 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.